Spotlight on Gynecology/Obstetrics

Credits: 0.50 CME
On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer
Robert Coleman, MD, FACS, FACOG
Postgraduate Institute for Medicine

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Gynecology/Obstetrics Presentations

0.50 CME
Postgraduate Institute for Medicine
On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: October 7, 2021
Expires: October 7, 2022
30 minutes to complete

Jointly Provided By

The Postgraduate Institute for Medicine and Bio Ascend

Target Audience

The target audience for this activity is community and academic medical oncologists, gynecologic oncologists, surgical oncologists, obstetricians and gynecologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with ovarian cancer.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Select genetic testing for patients with newly diagnosed advanced ovarian cancer
  • Utilize clinical features and genetic information to plan treatment for patients with newly diagnosed advanced ovarian cancer
  • Compare and contrast current and emerging treatment strategies for patients with newly diagnosed ovarian cancer
  • Manage adverse events associated with maintenance therapy for patients with newly diagnosed advanced ovarian cancer

Activity Description

On Topic Virtual Roundtable™: Deciphering the Decisions in Newly Diagnosed Advanced Ovarian Cancer aims to focus on critical care decisions for patients with newly diagnosed advanced ovarian cancer. This activity will also provide a unique take by including the patient voice as part of the discussion. You’ll hear directly from a patient living with ovarian cancer who will share her experience along with important information she feels physicians should know when caring for these patients.

Statement of Educational Need

Ovarian neoplasms, consisting mostly of epithelial ovarian cancer (~90%), is the leading cause of death from gynecologic cancer in the United States. Improved outcomes from multiple phase 3 studies have shifted the treatment paradigm for patients with newly diagnosed advanced ovarian cancer. This progress brings new challenges, which force HCPs to make critical decisions that require extensive knowledge and careful thought. This program will help clinicians make those critical decisions leading to improved care for patients with this challenging disease.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Moderator

Robert Coleman, MD, FACS, FACOG
Chief Scientific Officer
Texas Oncology - US Oncology Research
Houston, Texas

Consultant/Advisory Board: Deciphera, Agenus, Gradalis, Alkermes, Epsilogen, Karyopharm, Merck, GSK, Seagen, Slovis, Novocure, DNAMx, AstraZeneca, Genelux, Genentech/Roche, Abbvie, OncXerna
Research Funding: Merck, Abbvie, AstraZeneca, Seagen, Genentech/Roche

Faculty

Angeles Alvarez Secord, MD
Professor of Obstetrics and Gynecology
Duke Cancer Institute
Durham, North Carolina

Consulting Fees/Advisory Board: Myriad, AbbVie, Aravive, AstraZeneca, Eisai, Tesaro/GSK, Regeneron
Research Funding: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep Ltd, Merck, Oncoquest, PharmaMar, Roche/Genentech, Seagen Inc., Tesaro/GSK, VBL Therapeutics, National Cancer Trial Network


Paula Anastasia, RN, MN, AOCN
GYN-Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, California

Consulting Fees: Merck Advisory Board
Speakers’ Bureau (non-branded): Genentech


Patient Advocate and Ovarian Cancer Survivor
Kathy Jennings


No relevant financial relationships to disclose

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Merck.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

info@bioascend.com